ASX Penny Stock Highlights: Immutep, Alfabs Australia and Dusk Group

Immutep, a biotech company, is developing LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia with a market cap of A$404.78 million. Despite being pre-revenue and unprofitable, Immutep has shown promising results in clinical trials for its immunotherapy segment, with potential future growth avenues highlighted by recent positive trial data and FDA Fast Track designations. The company's financial stability is bolstered by sufficient cash reserves exceeding its liabilities.